Investors Eye Biotech Sector as Cancer Therapy Market Surges
The article continued: The Center for Innovation and Translation of Point of Care Technologies for Equitable Cancer Care (CITEC) has launched a global initiative focused on accelerating next-generation cancer detection technologies. With demand for advanced oncology solutions increasing, industry projections suggest significant market expansion, as DelveInsight Business Research forecasts a 9.12% compound annual growth rate (CAGR)—pushing the global cancer therapy market to an estimated $285.96 billion by 2030.
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage company focused on immunotherapy for cancer, continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep's potential in hard-to-treat cancers. Oncolytics was pleased to highlight two significant developments for its immunotherapy, pelareorep: the safety and regulatory clearance to advance enrollment in its pancreatic cancer study and the recent presentation of new efficacy and safety data at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in late January.
"We're hitting critical milestones that validate our progress and set the stage for what we believe will be an exciting year," said Wayne Pisano , Interim CEO and Chair of Oncolytics' Board of Directors. "With positive feedback from regulators in place, we're advancing our pancreatic cancer study toward full enrollment, and our ASCO GI presentations highlighted pelareorep's strong safety and efficacy results in two hard-to-treat cancers. We remain focused on bringing new treatment options to patients while creating value for shareholders as we move forward in 2025."
Germany's Paul-Ehrlich-Institute (PEI) has granted Oncolytics Biotech approval to proceed with full enrollment in its pancreatic cancer trial (GOBLET Cohort 5) following a successful safety review. This milestone allows the study to advance as planned, with 30 patients set to participate in Stage 1 across two treatment arms evaluating pelareorep in combination with modified FOLFIRINOX, with or without atezolizumab. With the safety run-in complete, Oncolytics will continue gathering safety data, with an initial efficacy readout expected later this year. This progress reinforces pelareorep's potential in one of the most aggressive and challenging-to-treat cancers, bringing the company one step closer to expanding its clinical impact in gastrointestinal oncology.
At ASCO GI 2025, Oncolytics Biotech presented new clinical data reinforcing pelareorep's potential in two difficult-to-treat cancers: anal and pancreatic cancer. In anal cancer, patients receiving pelareorep + atezolizumab continue to show stronger-than-expected responses, outperforming results seen in published studies using checkpoint inhibitors alone. In pancreatic cancer, pelareorep has previously demonstrated a strong efficacy signal in combination with gemcitabine, nab-paclitaxel, and atezolizumab. The latest findings confirm a favorable safety profile when using pelareorep with a different chemotherapy regimen (modified FOLFIRINOX), with and without atezolizumab, potentially broadening its clinical applications. These results further de-risk pelareorep's development and could support the advancement into larger, registration-enabling trials, bringing the therapy closer to addressing major unmet needs in gastrointestinal oncology.
As Oncolytics moves into a pivotal year, multiple high-impact milestones are set to shape the company's progress. Upcoming data readouts from ongoing gastrointestinal cancer trials will provide further insights, including translational results that help characterize pelareorep's mechanism of action. Additionally, regulatory interactions throughout the year could play a crucial role in accelerating future trials, bringing pelareorep closer to potential registration-enabling studies in both breast and gastrointestinal cancers. These milestones position Oncolytics for continued momentum as it advances its clinical pipeline toward broader patient impact.
"We're seeing clinical validation across multiple studies," added Pisano. "With encouraging regulatory interactions in hand and data readouts ahead, 2025 is shaping up to be an exciting year for Oncolytics and our investors. As we have shown in GOBLET, BRACELET-1, and numerous previous studies, pelareorep has a favorable safety profile and efficacy signals across multiple indications with a high unmet need. We are excited about the potential for moving to a registration-enabling study in breast cancer and advancing our clinical program in gastrointestinal cancers."
In other recent industry developments and happenings in the market include:
GRAIL, Inc. (NASDAQ: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, and Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, recently announced the initial phase of a program to improve provider access to GRAIL's Galleri ® multi-cancer early detection (MCED) test.
Providers can now order the Galleri test directly from GRAIL through the Quest Diagnostics connectivity system. The Quest Diagnostics connectivity system enables providers in the United States to order and receive reports of laboratory tests electronically through Quest's Quanum laboratory portal and more than 900 electronic health record (EHR) systems. More than 500,000 providers used the Quest connectivity system last year.
" Quest Diagnostics and GRAIL share a commitment to improving access to cancer screening and have worked productively together to enable patient access to GRAIL's Galleri test via Quest's phlebotomy network since 2021," said Mark Gardner, Senior Vice President, Molecular Genomics and Oncology for Quest Diagnostics. "Integrating GRAIL's Galleri test into the Quest connectivity system is the next step in this collaboration. We expect it to increase patient access by giving Quest's provider clients the ability to seamlessly order the test through Quest, same as they do for other blood work. This collaboration brings to life the tremendous value of Quest's ability to scale diagnostic innovation to make it accessible for all."
Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, recently announced it entered into a binding LOI to acquire Predictive Oncology Inc. (NASDAQ: POAI) in an all-stock transaction.
By leveraging Predictive Oncology's extensive biobank of 150,000 tumor samples, Renovaro gains a critical resource to accelerate biomarker discovery, optimize clinical trials, and enhance decision-support tools across multiple cancer types. The combined organization will operate a state-of-the-art, CLIA, NYSDOH, and CA-certified laboratory staffed by an experienced team, streamlining diagnostic test development and validation while expanding market reach in Europe . Additionally, Renovaro introduces a novel in vivo chemosensitivity and resistance assay, improving cancer treatment predictions for European patients and enabling multi-omic collaborations for drug discovery.
"We recognize that by integrating Predictive Oncology's AI-driven drug discovery platform and vast biobank of more than 150,000 patient tumor samples, 200,000 pathology slides and decades of longitudinal drug response data with Renovaro's multi-disciplinary artificial intelligence, multi-omics and multi-modal data expertise, we are opening to door to diagnostic, therapeutic and drug discovery possibilities that we otherwise would never have considered," said Raymond Vennare , CEO of Predictive Oncology.
In the long term, this partnership lays the foundation for a global point-of-care cancer solution, integrating Predictive Oncology's AI-driven small molecule solid tumor expertise with Renovaro's AI-powered liquid biopsy and cancer vaccine programs. This first-in-class, full-stack clinical service has the potential to advance cancer therapy at every stage—from early detection and diagnostics to personalized treatment and biomarker discovery—ultimately improving patient outcomes and reducing costs.
" Renovaro is on a quest to offer cancer patients early diagnostic options, treatment protocols, and recurrence monitoring," said David Weinstein , CEO of R enovaro. " Predictive Oncology will enhance our capabilities by assisting oncologists with patient specific diagnostic and therapeutic clinical support data. Predictive Oncology's proprietary AI/ML platform has been proven to predict tumor-drug response with 92% accuracy which, I believe, will allow us to launch as a decision support platform for medical oncologists in 2025. As importantly, there are strong synergies with Predictive's small molecule solid tumor drug-tumor response modeling capabilities and Renovaro's liquid biopsy approach to early cancer detection and monitoring."
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
16 minutes ago
- Globe and Mail
PBF Energy (PBF) Q2 Revenue Falls 14%
Key Points Non-GAAP earnings per share of $(1.03) in Q2 2025 topped analyst estimates by $0.23 despite a wider loss from the prior year. Revenue of $7.47 billion exceeded expectations but declined 14.4% from $8.74 billion in GAAP revenue in Q2 2024. Martinez refinery continued only partial operations due to fire recovery, skewing performance while insurance recoveries buffered headline results. These 10 stocks could mint the next wave of millionaires › PBF Energy (NYSE:PBF), an independent petroleum refiner and supplier of transportation fuels, released its second quarter 2025 earnings on July 31, 2025. The report highlighted a mixed quarter: non-GAAP earnings per share were $(1.03), better than the analyst consensus non-GAAP loss of $(1.26), and revenue was $7.48 billion, beating estimates by more than $500 million. Still, both earnings and revenue were down from the prior year, with revenue declined 14.4% year over year. The quarter was shaped by the continued partial shutdown of the Martinez refinery and operational headwinds, with insurance proceeds from the Martinez incident softening the impact of operating losses. Overall, results beat analyst estimates, but the company's core profitability remained negative after adjusting for insurance and other special items. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (Non-GAAP) $(1.03) $(1.26) $(0.54) (90.7 % decrease) Revenue (GAAP) $7.47 billion $6.97 billion $8.74 billion (14.4 %) Income from Operations (GAAP) $43.0 million $(74.6) million NM EBITDA (Non-GAAP) $51.8 million $86.2 million (39.9%) Gross Refining Margin per Barrel (Non-GAAP) $8.38 $8.12 3.2% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Company Overview and Key Priorities PBF Energy (NYSE:PBF) operates six petroleum refineries across the United States, with a combined processing capacity near 1 million barrels per day as of December 31, 2024. Its operations produce gasoline, diesel, jet fuel, and other refined products. A central competitive factor is the Nelson Complexity Index—a measure of a refinery's ability to upgrade lower-cost crude into high-value products. PBF's average complexity is high, providing flexibility and resilience through changing market cycles. The company's recent focus has centered on operational efficiency, cost containment, maintaining safe and reliable operations, and restoring damaged assets. Key priorities include managing the cost of regulatory compliance, improving operating expenses, and deploying the Refining Business Improvement (RBI) initiative that aims to identify and capture over $200 million in annualized run-rate savings. Effective management of feedstock supply and logistics is also critical for sustainability. Quarter in Review: Performance Drivers and Challenges This quarter was defined by ongoing fallout from the Martinez refinery fire that occurred earlier in 2025. Production averaged 845,800 barrels per day, down from 926,700 barrels per day in the same quarter last year. The Martinez facility operated at limited capacity in the 85,000–105,000 barrels per day range as repairs advanced, restricting West Coast system throughput. West Coast throughput dropped sharply year over year, landing at 203,500 barrels per day compared to 296,700 barrels per day in Q2 2024, while gross margin per barrel in that region swung from a positive $0.34 in Q2 2024 to a negative $(9.54) (GAAP basis) due to both the outage and higher compliance costs. System-wide, the gross refining margin per barrel was $8.38, but GAAP gross margin was negative, reflecting the heavy effect of Martinez-related charges. Operational expense per barrel increased to $7.96 from $6.94 in Q2 2024, with West Coast expenses especially elevated at $15.73 per barrel. Despite these pressures, an insurance recovery payment of $250 million helped offset Martinez losses in the reported results. Management expects full Martinez operations to be restored by year-end 2025, depending on regulatory and supply chain timelines. Market dynamics continued to challenge overall performance. The Brent crude oil price averaged $67.70 per barrel (down from $85.02 in Q2 2024), but narrow light-heavy crude price differentials eroded potential cost advantages for complex refineries like PBF's. The proportion of heavy crude processed fell to 25%, limiting feedstock flexibility. Meanwhile, Renewable Identification Number (RIN) costs—an environmental compliance expense tied to U.S. renewable fuel requirements—jumped from $3.38 to $6.14 per barrel-equivalent year over year, significantly inflating compliance costs, especially for California operations facing strict state rules. Supply and market conditions are also shifting. California faces a shrinking in-state supply as additional refinery closures approach, with management projecting the need to import over 250,000 barrels per day of gasoline to meet demand by next year. PBF's refineries, including Martinez once full production resumes, are expected to remain essential suppliers to that market. The Logistics segment delivered stable revenue of $98 million, and PBF sold two non-core terminals for $175 million—a transaction at more than 10 times EBITDA, according to management, with the sale agreement announced April 30, 2025. Notably, these terminal sales will not disrupt refining operations, as access is maintained through long-term contracts. The Renewable Diesel segment, operated in a joint venture with St. Bernard Renewables (SBR), produced an average of 14,200 barrels per day of renewable diesel—a biofuel made from fats and oils. Management guided for further growth in the next period. Despite management expecting improved margins as higher RIN prices support the economics of renewable diesel going forward. Balance sheet pressures persisted as reduced free cash flow and insurance-timing differences drove up total debt to $2.39 billion as of June 30, 2025, compared with $1.46 billion as of December 31, 2024. The total debt to capitalization ratio rose to 31% as of Q2 2025 from 20% as of Q4 2024, and net debt to capitalization increased to 26% as of June 30, 2025. Working capital outflows and Martinez-related expenses weighed on cash flow, but insurance recoveries and terminal sale proceeds should support liquidity in coming quarters. The company maintained its quarterly dividend at $0.275 per share, unchanged despite recent losses. Looking Ahead: Guidance and Investor Considerations For Q3 2025, management forecasts throughput of 865,000–915,000 barrels per day, up from 839,100 barrels per day in Q2 2025 but still trailing last year's levels. The company reaffirmed full-year 2025 capital expenditure guidance at $750–775 million, excluding Martinez repairs, which will be completed under insurance coverage. PBF expects the benefits of its cost-saving RBI initiative to accelerate into 2026, targeting over $350 million in run-rate savings by year-end 2026. No additional formal forward earnings guidance was issued for fiscal 2025. Management noted ongoing market volatility, particularly in crude spreads and regulatory costs, as key watch points for future quarters. Delays or added regulatory burdens could continue to constrain performance, particularly on the West Coast. Full reliance on insurance proceeds for Martinez recovery and successful execution of cost initiatives are central to management's current strategy. PBF does pay a dividend. The quarterly dividend was maintained at $0.275 per share, unchanged from previous quarters. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,049%* — a market-crushing outperformance compared to 182% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. *Stock Advisor returns as of July 29, 2025
Globe and Mail
2 hours ago
- Globe and Mail
DXP Enterprises, Inc. Announces Second Quarter 2025 Earnings Release and Conference Call
DXP Enterprises, Inc. (the 'Company') (NASDAQ: DXPE), a leading business to business products and service distributor that adds value and total cost savings solutions to MRO and OEM customers in virtually every industry, plans to issue a press release announcing its financial results for the quarter ended June 30, 2025, on Wednesday, August 6 th. The earnings announcement will be released after the market closes. DXP will host a conference call, to be webcast live, on the Company's website ( at 10:30 AM Central Time on Thursday, August 7 th. The call and an accompanying slide presentation will be on the "Investor Relations" section of DXP's website at A replay of the webcast will be available shortly after the conclusion of the presentation. DXP's earnings press release, slides and other related presentation materials will be posted to the "Investor Relations" section of DXP's website under the subheading "Financial Information" after the market closes on the date of the earnings call and will remain available following the call. Web participants are encouraged to go to the Company's website ( at least 15 minutes prior to the start of the call to register, download and install any necessary audio software. The Private Securities Litigation Reform Act of 1995 provides a 'safe-harbor' for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made by or to be made by the Company) contains statements that are forward-looking. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future; and accordingly, such results may differ from those expressed in any forward-looking statement made by or on behalf of the Company. These risks and uncertainties include, but are not limited to; ability to obtain needed capital, dependence on existing management, leverage and debt service, domestic or global economic conditions, and changes in customer preferences and attitudes. For more information, review the Company's filings with the Securities and Exchange Commission.
Globe and Mail
2 hours ago
- Globe and Mail
Why Palo Alto Networks Stock Plummeted by More Than 5% Today
Key Points There were doubts about the company's latest deal. It has agreed to acquire peer CyberArk for around $25 billion in cash and stock. 10 stocks we like better than Palo Alto Networks › Palo Alto Networks (NASDAQ: PANW) made waves Wednesday when it announced a pricey acquisition, and on Thursday, investors were clearly getting worried about the cost. Analysts, too, started to express concern, with two even downgrading their recommendation on the shares. With these headwinds blowing in its face, Palo Alto's stock lost more than 5% of its value during the latter part of the trading day. That was a far steeper decline than the 0.4% slide of the benchmark S&P 500 index. The $25 billion question Palo Alto's asset-to-be is peer cybersecurity company CyberArk Software, for which it agreed to pay roughly $25 billion in a cash-and-stock deal. CyberArk is a specialist in the niche area of identity security, and Palo Alto said that its ownership of the business will make the segment "a core pillar of the company's multi-platform strategy." The buyout has been unanimously approved by the boards of directors of both companies, and is anticipated to close in the second half of Palo Alto's fiscal 2026. Palo Alto certainly isn't a poor company. Nevertheless, $25 billion is a major outlay. Several analysts don't think that's worth it, including that frequent downgrader, KeyBanc's Eric Heath. Well before market open Thursday, Heath enumerated several major strategic concerns about the deal, according to reports. He cast doubt on the potential synergies of the two businesses, and opined that customers are likely to prefer using a specialized company purely for identity security rather than a broad cybersecurity services provider, among other factors. Unkind cuts? Other analysts were similarly bearish, although they didn't go as far as to downgrade their Palo Alto recommendations. They did reduce their price targets on the shares, however. That clutch of pundits included Mizuho's Gregg Moskowitz, who cut $15 from his fair value assessment on the stock to $210 per share. He did maintain his outperform (i.e., buy) recommendation, however. Should you invest $1,000 in Palo Alto Networks right now? Before you buy stock in Palo Alto Networks, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palo Alto Networks wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
